Purpose: We hypothesized that functional TGF␤1 SNPs increase TGF␤/BMP signaling imbalance in BMPR2 mutation heterozygotes to accelerate the age at diagnosis, increase the penetrance and SMAD2 expression in familial pulmonary arterial hypertension. Methods: Single nucleotide polymorphism genotypes of BMPR2 mutation heterozygotes, age at diagnosis, and penetrance of familial pulmonary arterial hypertension were compared and SMAD2 expression was studied in lung sections. Results: BMPR2 mutation heterozygotes with least active -509 or codon 10 TGF␤1 SNPs had later mean age at diagnosis of familial pulmonary arterial hypertension (39.5 and 43.2 years) than those with more active genotypes (31.6 and 33.1 years, P ϭ 0.03 and 0.02, respectively).
Pulmonary arterial hypertension (PAH) is a progressive, fatal disease caused by proliferative occlusion of the pulmonary arteries due to vascular remodeling. Familial PAH (FPAH) is an autosomal dominant disorder that exhibits variable expression, reduced penetrance, skewed female:male ratio of 2.4:1 and anticipation. 1, 2 In 2000, mutations in the Bone Morphogenetic Protein Receptor Type 2 (BMPR2) gene in the TGF␤ Superfamily were reported to cause FPAH. 3, 4 Subsequently, over 140 different BMPR2 mutations have been detected in FPAH and most are predicted to cause a loss of receptor function (haploinsufficiency), either through missense, nonsense or frameshift mutations, or through splicing errors. [5] [6] [7] [8] Recently, these as well as deletion/duplication BMPR2 mutations were reported to occur in the majority (82%) of FPAH cases. 9 Although BMPR2 mutations cause FPAH, the pathophysiology of this complex disease remains unclear. 10 The observation that many of those with a BMPR2 mutation do not develop FPAH suggests that susceptibility and modifier genes, anticipation, as well as environment may all play important roles in determining the reduced penetrance, skewed gender ratio, variations in clinical severity and progression, and possibly differences seen in the response to treatment.
Anticipation is the tendency in certain genetic disorders for those in successive generations to present at an earlier age and/or with more severe manifestations. It is often seen in disorders resulting from the expression of a trinucleotide repeat expansion that tends to increase in size and have a more significant effect when passed from one generation to the next. 11 No trinucleotide repeat or other expansions in BMPR2 have been reported to cause FPAH and the molecular basis of anticipation in FPAH is poorly understood. 1, 2 Nonsense-mediated decay (NMD) is a messenger RNA (mRNA) surveillance system that degrades transcripts containing premature termination codons (PTCs) to prevent translation of unnecessary or harmful transcripts. We have previously shown by analysis of BMPR2 mRNAs that some mutations produce stable transcripts whereas others generate PTCs which trigger mRNA degradation by NMD. 7, 9 Failure to eliminate mRNAs with PTCs can result in synthesis of abnormal proteins that can be toxic to cells through dominant negative or gain of function effects. 12, 13 Ligands for BMPR2, called bone morphogenetic proteins (BMPs), are signaling molecules that are also members of the TGF␤ superfamily. BMPs are synthesized and released from a variety of cell types including pulmonary artery smooth muscle and endothelial cells. They induce formation of heterodimeric complexes between Type I and II receptors that activate downstream signaling pathways through phosphorylation and/or mitogen activated kinases. 14,15 SMADS1, 5, and 8 mediate intracellular signaling of BMP whereas SMADS2 and 3 transduce TGF␤ signaling. SMAD4 is a common mediator that is required for both pathways. 16 In addition, other signaling systems that influence vascular tone, function, and remodeling have been associated with PAH. [17] [18] [19] Multiple studies show that serotonin and its transporter (SERT) play a critical role in the pulmonary vascular smooth muscle hyperplasia and vascular remodeling found in PAH and SERT polymorphisms weakly correlate with severity or age at diagnosis (AAD) of FPAH. 20 -22 Susceptibility genes have functional variants that affect causes of disease. Modifier genes differ in that they are genetic variants that affect the clinical manifestation of disease (as opposed to liability). In contrast to susceptibility genes, the identification of modifier genes has proven elusive. 23 TGF␤ single nucleotide polymorphisms (SNPs) have been reported to modify the severity of cystic fibrosis (CF). 24 Drumm et al. 24 reported significant allelic and genotypic associations between the CF phenotype and -509 and codon 10 TGF␤1 SNPs. The -509 TGF␤ C/T SNP explains 8.2% of the additive genetic variance in TGF␤ concentration due to effects on a Yin Yang 1 binding site and transcriptional suppression of the -509 C allele by AP1. [25] [26] [27] The codon 10 C SNP allele with higher levels of TGF␤1 mRNA and protein exhibits association with pulmonary fibrotic and chronic obstructive pulmonary disease. 28 -30 The more active -509 TT and codon 10 CC TGF␤1 SNP genotypes associate in CF studies with worse lung function, and the TGF␤1 codon 10 CC genotype had an odds ratio of 2.2 with the most severe reductions in forced expiratory volume in the first second (FEV1). 24 Although the codon 10 CC SNP genotype correlated with increased TGF␤ expression, secretion and levels in a variety of other conditions, the mechanisms by which the SNP genotype may function with other genetic or environmental factors to affect the severity of CF is unknown. 23 Variation in the severity of symptoms of inborn errors is often attributed to the effects of specific mutations. However, some affected individuals can have partial defects in more than one pathway, or at multiple steps in a single pathway. These individuals can show clinical symptoms consistent with a homozygous defect in the affected pathway even though they do not have a complete deficiency in any one enzyme. Vockley et al. 31 and Schuler et al. 32 coined the term "Synergistic Heterozygosity" for such individuals having clinically significant metabolic problems due to the compound effects of these partial defects. We have incorporated this idea of Synergistic Heterozygosity into our hypothesis that heterozygosity for both a rare BMPR2 mutation and common TGF␤ SNPs in the TGF␤/ BMP signaling pathways interact to influence expression of the FPAH phenotype.
MATERIALS AND METHODS

Patient recruitment and evaluation
Study subjects were recruited over a 20-year period through our Pulmonary Hypertension Center, the Pulmonary Hypertension Association, and the National Institutes of Health Clinical Trials website (http://clinicaltrials.gov). The 81 family members with FPAH and a proven BMPR2 mutation were treated at centers throughout the United States and most are deceased. These 81 individuals were members of 55 nonrelated FPAH kindreds. Of these, 40 families were represented by one subject, whereas 11 families contributed two subjects. The remaining 19 affected subjects represented four different families, with three, four, five, and seven subjects, respectively. PAH was diagnosed by lung pathology showing plexogenic pulmonary arteriopathy in the absence of alternative causes such as congenital heart disease, or by clinical and cardiac catheterization criteria. The latter included a mean pulmonary arterial pressure of Ͼ25 mm Hg with a pulmonary capillary or left atrial pressure of Ͻ15 mm Hg, and exclusion of other causes of pulmonary hypertension in accordance with accepted international standards of diagnostic criteria. 33, 34 Pulmonary arterial pressures were similar, regardless of the age at diagnostic cardiac catheterization. Diagnosis of FPAH required a well-documented family history of PAH and clinical confirmation of FPAH by the above criteria. Clinical information on current age, AAD, gender, and PAH status was confirmed by review of medical records. AAD for patients with FPAH was determined by the date of diagnostic cardiac catheterization or clinical evaluation that established the diagnosis. A careful scrutiny of available clinical data including AAD resulted in the inclusion of 61 of the 81 affected subjects for the analysis of factors influencing AAD. For the 39 unaffected members of our FPAH families who also had a proven BMPR2 mutation, their age on the date of our last contact with them at study enrollment and blood draw was recorded and their AAD was censored at the age of enrollment. Thus, all subjects in this study were proven to have BMPR2 mutations and were classified as affected based on the presence of the FPAH diagnosis, versus mutation carriers without clinical evidence of PAH. The study was approved by the Institutional Review Board at Vanderbilt University Medical Center, and written informed consent was obtained from all study subjects.
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Genotyping genomic DNAs for TGF␤ SNPs
Genomic DNA was prepared from whole blood using Gentra Systems' Puregene® DNA Purification Kit (Minneapolis, MN) according to the manufacturer's protocol. Samples were genotyped for TGF␤1 -509 and codon 10 SNPs by polymerase chain reaction (PCR) amplification of 25 ng of genomic DNA using Elongase Enzyme Mix (Invitrogen, Carlsbad, CA) and 10 M of each of the oligonucleotide primers. The sequences for the TGF␤1 -509 primers were 5Ј-CAGTTGGCGAGAACAGT-TGG-3Ј for the forward primer and 5Ј-CAGATGCGCTGTG-GCTTT-3Ј for the reverse primer. The sequences for the TGF␤1 codon 10 primers were 5Ј-GCCACAGATCCCCTAT-TCAA-3Ј for the forward primer, and 5Ј-TCGATAGTCTTG-CAGGTGGA-3Ј for the reverse primer. PCR cycling conditions for TGF␤1 -509 were 94°C, 30 seconds; 35 cycles of 94°C, 30 seconds; 58°C, 45 seconds; 68°C, 45 seconds; then 68°C, 3 minutes. PCR cycling conditions for TGF␤1 codon 10 were 95°C, 1 minute; 35 cycles of 95°C, 1 minute; 61°C, 1 minute; 68°C, 1 minute; then 68°C, 10 minutes. Before sequencing, amplified products were purified with ExoSAP-IT (USB Corporation, Cleveland, OH). Sequencing reactions were performed using a forward primer (5Ј-GCCCAGTTTC-CCTATCTGT-3Ј) for TGF␤1 -509 and another forward primer (5Ј-CCGTGGGATACTGAGACACC3Ј) for TGF␤1 codon 10 and a BigDye Terminator v3.1 Cycle Sequencing Kit according to the manufacturer's protocol (Applied BioSystems, Foster City, CA). Samples were then analyzed by capillary electrophoresis using a 3100 Genetic Analyzer (Applied Biosystems). Genotypes were determined by analysis with Mutation Surveyor Software (SoftGenetics, State College, PA).
NMD classification
BMPR2 mutations that produce stable mutant BMPR2 transcripts that do not activate NMD, are referred to as NMDϪ whereas those whose transcripts are degraded by NMD are classified as NMDϩ. NMD status was based on the stability of the mutant transcript in lymphoblastoid cell lines derived from individuals with each mutation following incubation with or without an NMD inhibitor (Puromycin). 7, 9 All NMDϪ BMPR2 transcripts showed roughly equal proportions of mutant and normal BMPR2 transcripts with and without lymphoblastoid cell line incubation with Puromycin.
Preparation of lung sections and SMAD analysis
Immunohistochemical analysis of human tissue sections for phosphorylated SMAD2 (pSMAD2) was performed using reagents and methods that have been previously described. 35 Samples were derived from control individuals without disease (death caused by trauma) and diseased control patients with either pulmonary hypertension associated with congenital heart disease/Eisenmenger syndrome or FPAH due to mutations in the BMPR2 gene (n ϭ 5 in each group). The images were analyzed independently by two pathologists who were blinded to clinical diagnosis.
Study design
We hypothesized that Synergistic Heterozygosity for functional TGF␤1 SNPs further increases the TGF␤/BMP signaling imbalance in BMPR2 mutation heterozygotes (MH) to modulate the AAD and the penetrance of FPAH and is associated with increased SMAD2 expression in the lung. To test our hypotheses we genotyped the TGF␤1 SNPs of BMPR2 MH and compared both the AAD and penetrance of FPAH among the TGF␤1 SNPs genotypes. We also examined the expression of TGF␤/BMP dependent SMAD2 in lung sections from individuals with FPAH.
Data analysis and statistics
The test proposed by Weir 36 was applied for Hardy Weinberg equilibrium (HWE). Kaplan-Meier disease free survival curve for AAD was constructed for TGF␤1 SNP genotype groups. Log rank test was used to compare the curves between groups. For FPAH patients, their AAD was compared using Wilcoxon rank sum test because the AAD was not normally distributed. P values Ͻ 0.05 were considered statistically significant and all tests were two-tailed. Analysis of the binary variable penetrance was undertaken using the chi-square test for trend (Mantel-Haenszel test) across the three genotypes for each SNP. P values Ͻ 0.025, in concordance with techniques of the Bonferroni correction, were considered statistically significant and all tests were two-tailed. Statistical analyses were performed on a personal computer with the statistical package SPSS for Windows (Version 14.0, SPSS, Chicago) and the statistical software R (www.r-project.org).
RESULTS
TGF␤1 SNP genotypes
The TGF␤ -509 and codon 10 SNP genotypes for affected individuals are shown in Tables 1 and 2 . The P values of tests for HWE for the affected (FPAH patients) were 0.723 and Ͻ0.001 for TGF␤ -509 and codon 10 SNP genotypes, respectively.
AAD of FPAH and TGF␤1 SNP genotypes
BMPR2 MH having the least active (CC) as opposed to more active (CT/TT) -509 TGF␤1 SNP genotypes had mean ages at Table 3 ). BMPR2 MH with the least active (TT) as opposed to more active (CT/CC) codon 10 TGF␤1 SNP genotypes had mean ages at diagnosis of 43.2 and 33.1 years, respectively (P ϭ 0.02 Wilcoxon, Table 4 ).
Kaplan-Meier analyses
Kaplan-Meier analyses showed that those having the least active (CC) versus the more active (CT/TT) TGF␤1 -509 SNP genotypes had later ages at diagnosis (P ϭ 0.038 log rank, Fig.  1 ). Also those having the least active (TT) versus the more active (CT/CC) TGF␤1 codon 10 SNP genotypes had later ages at diagnosis (P ϭ 0.020 log rank, Fig. 1 ).
Penetrance of FPAH in BMPR2 heterozygotes with TGF␤1 SNP genotypes
The proportion of all NMDϪ BMPR2 MH who had FPAH was 0.33, 0.72, and 0.80 for those with CC (least active), CT (intermediate) and TT (most active) -509 genotypes (P ϭ 0.003 from 2 trend test, Fig. 2 ). The proportion of all NMDϪ BMPR2 MH who had FPAH was 0.33, 0.72, and 0.75 for those with 0 -1, 2, or 3-4 active -509 or codon 10 SNP alleles (P ϭ 0.005 from 2 trend test, Fig. 3 ).
SMAD analysis of lung sections
When compared with control individuals, the small to medium sized muscular arteries in the pulmonary circulation of individuals with FPAH showed increased TGF␤ signaling in the medial layer of the vessel wall, as evidenced by increased nuclear accumulation of phosphorylated SMAD2 (pSMAD2), an intracellular mediator of the TGF␤ transcriptional response (Fig. 4) . This observation is unlikely to simply reflect a consequence of a chronic increase in pulmonary arterial pressure because increased TGF␤ signaling was not observed in the pulmonary vasculature of individuals with Eisenmenger syndrome, a form of secondary pulmonary hypertension due to a chronic shunting of blood flow into the pulmonary circulation from the high-pressure systemic circulation (Fig. 4) .
DISCUSSION
Although FPAH is autosomal dominant it has reduced penetrance and variable age of onset in BMPR2 MH. 1, 17, 18 This suggests that the genetic background on which BMPR2 mutations occur, along with the expression levels of the mutant and normal BMPR2 alleles, and possible environmental factors may affect penetrance and age of onset of FPAH. Identifying the genetic variations in susceptibility and modifier genes that enhance or inhibit phenotypic expression could provide insights that might allow directed intervention strategies to be developed. To better understand the role of modifier genes in FPAH we studied the relationship between variations in the number of active TGF␤ SNPs and the AAD and penetrance of FPAH in BMPR2 MH.
The TGF␤1 -509 and codon 10 SNP gene frequencies were C ϭ 0.69, T ϭ 0.31 and C ϭ 0.43, T ϭ 0.57, respectively (Tables  1 and 2 ). From these frequencies the expected numbers of individuals of various genotypes were calculated using the Hardy Weinberg formula. Tests for HWE showed that the codon 10 genotypes deviated from HWE. To exclude the possibility of genotyping errors, we regenotyped both SNPs from fresh aliquots of all genomic DNA samples and genotyping errors were ruled out. One possible explanation for the deviation from HWE may be our study ascertainment. In this aspect of our study, every subject has a BMPR2 mutation. Thus, our study sample comprises a stratum from the general population, rather than a representative sample. Secondly, this analysis fo- Phillips III et al.
cuses on the affected, and HWE is generally expected to be distorted in the case sample in the region of association. 37 We hypothesized that increased TGF␤ activation from more active TGF␤ alleles, coupled with reduced BMPR2 function from heterozygosity for a BMPR2 mutation can further increase the imbalance in the TGF␤/BMP signaling ratio to contribute to an earlier AAD and increased penetrance of FPAH. We tested our hypotheses first by studying the association of common, functional TGF␤1 SNPs and AAD of those having FPAH (Tables 3 and 4 and Figs. 1 and 2) . We also determined the penetrance of FPAH in all NMDϪ BMPR2 MH with different TGF␤ SNP genotypes (Figs. 3 and 4) . Both earlier AAD and increased penetrance was seen in those with more active TGF␤ SNP genotypes. To evaluate the potential that familial clustering may contribute to these findings, we excluded families having more than two affected individuals, and reanalyzed the data. Despite a loss of power due to the exclusion of 19 affected subjects and 17 unaffected heterozygotes, a significantly younger AAD and increased penetrance was again seen in those with more active TGF␤ SNP genotypes. In addition, many of the remaining subjects from the 11 FPAH kindreds with two affected members were distantly related. Thus, even for the few remaining closely related members the probability for concordance for TGF␤ SNP genotype is expected to be similar to that of the general population because of the high frequencies of the SNP alleles. Finally, when we selected only the youngest affected BMPR2 MH from each family for which mutation and SNP data were available we observed the same affects of the SNPs on AAD (data not shown). Thus, we feel that the contribution of familial clustering is negligible. Our finding that TGF␤1 SNPs are associated with AAD and penetrance agrees with other evidence that increased TGF␤ activity promotes pulmonary vascular disease in genetic association studies. 24, 29, 30 Multiple, common human TGF␤ ligand SNPs are known to affect TGF␤ activation. 25, 38 In twin studies the TGF␤1 concentration was shown to be predominantly under genetic control (heritability estimate 0.54).
Also in support of our hypothesis that imbalanced TGF␤ /BMP signaling due to the presence of functional TGF␤ SNP alleles correlates with the AAD and penetrance of FPAH (Tables 3 and 4 and Figs. 1-3) , we found that SMAD2, which is induced by TGF␤, shows increased relative expression in lung sections of individuals with FPAH (Fig. 4) . Thus, our data in aggregate, suggest that common TGF␤ SNPs and rare BMPR2 mutations combine to increase the imbalance between the downstream pathways of TGF␤ and BMPR2 signaling to accelerate the diagnosis of FPAH (Fig. 5) .
Our data suggesting the potential role of TGF␤1 SNPs as modifier genes for FPAH are analogous to findings in CF. 24 Importantly, our results suggest that possible clinical therapies could target the TGF␤/BMP signaling imbalance. Several potential approaches exist, which, except for Losartan in Marfan syndrome and Imatinib (Gleevec) in PAH have not been tested in humans. 39 -41 Losartan attenuates pulmonary arterial remodeling and increased BMPR2 expression in a swine model. 42 Excess TGF␤1 activity is associated with Fibrillin mutations in Marfan syndrome. 43 Losartan is an angiotensin receptor blocker that reduces cleavage of TGF␤1 from its latent complex and prevents aortic aneurysms in a murine model of Marfan syndrome; it is in clinical trials in human Marfan syndrome. 44 The mechanisms underlying genetic anticipation in FPAH have yet to be elucidated. 1, 2 Our finding that the number of more active TGF␤ SNPs correlates with AAD and penetrance suggests that polymorphic variation in TGF␤1 may contribute to genetic anticipation. Our data indicate that BMPR2 MH with no active TGF␤1 -509 or codon 10 SNPs have a later AAD and constitute the minority (47 and 23%, respectively) of affected individuals studied (Tables 3 and 4) . Thus, BMPR2 MH with a later AAD are more likely to lack more active TGF␤ SNPs. Because population data indicates that most in the normal population would have one or more active alleles, offspring who inherit the BMPR2 mutation from an affected parent who has no active TGF␤ SNPs would likely have one or two active TGF␤ SNPs they inherited from their "normal " parent. Thus the child, unlike their BMPR2 heterozygous parent, would have one or two active TGF␤ SNPs that promote an earlier AAD and increased penetrance. Our conclusion regard- ing the potential effects of SNP genotypes on apparent anticipation is supported by our seeing the same effects of SNPs on AAD when we analyzed only the youngest affected BMPR2 MH from each family having available mutation and SNP data. In summary, we think this could exemplify "synergistic anticipation" in which older onset BMPR2 heterozygotes with younger onset children lack, while their children usually possess, common TGF␤ SNPs that are associated with earlier AAD of FPAH.
Finally, we think that the interactions between these TGF␤ SNPs and BMPR2 mutations create cases of double and triple heterozygosity that are examples of "Synergistic Heterozygosity." 31, 32 In the case of FPAH, heterozygosity for more active TGF␤ alleles is predicted to further increase the imbalance in the TGF␤/BMP signaling ratio that is already enhanced as a result of heterozygosity for a BMPR2 mutation. In FPAH this Synergistic Heterozygosity occurs in reciprocal, interactive pathways as shown in Figure 5 . It is also possible that additional, but as yet unknown, polymorphisms in other genes in the TGF␤ pathway may also contribute to this synergism.
